

Interview Summary	Application No.		Applicant(s)	
	09/597,102		PARSONS ET AL.	
	Examiner		Art Unit	
	Shaojia A. Jiang		1617	

All participants (applicant, applicant's representative, PTO personnel):

(1) Shaojia A. Jiang.

(3) Eyler, Yvonne.

(2) Padmanabhan, Sreeni.

(4) G. Patrick Sage.

Date of Interview: 08 August 2005.

(5) Michelle M. Cudaly

Type: a) ☐ Telephonic b) ☐ Video Conference

c) ☒ Personal [copy given to: 1) ☐ applicant 2) ☒ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☒ No.

If Yes, brief description: _____

Claim(s) discussed: all claims

Identification of prior art discussed: the cited prior art

Agreement with respect to the claims f) ☐ was reached. g) ☒ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: _____

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

The examiner would re-evaluate the 103 rejection and do update search. If the finality was withdrawn and new office action or new rejection^{was made}, the office would provide evidence showing either the same compound here were 5HT₃ ^{receptor antagonist} or the linking between 5HT₃ and NMDA receptor antagonists, or the same compound used in treating the same disease or NMDA receptor antagonist were well-known in the art to treat the specifically claimed disease.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

Examiner's signature, if required

- The 103 rejection is withdrawn.

SAD 8/8/05